645 related articles for article (PubMed ID: 25928246)
1. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract][Full Text] [Related]
2. Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma.
Wang X; Goldstein D; Crowe PJ; Yang M; Garrett K; Zeps N; Yang JL
Oncotarget; 2016 Apr; 7(16):21496-509. PubMed ID: 26909593
[TBL] [Abstract][Full Text] [Related]
3. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
5. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
6. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
You KS; Yi YW; Kwak SJ; Seong YS
Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
[TBL] [Abstract][Full Text] [Related]
8. Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Yar Saglam AS; Alp E; Elmazoglu Z; Menevse S
Hum Exp Toxicol; 2016 May; 35(5):526-43. PubMed ID: 26183715
[TBL] [Abstract][Full Text] [Related]
9. Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
Murone M; Vaslin Chessex A; Attinger A; Ramachandra R; Shetty SJ; Daginakatte G; Sengupta S; Marappan S; Dhodheri S; Rigotti S; Bachhav Y; Brienza S; Traxler P; Lang M; Aguet M; Zoete V; Michielin O; Nicholas C; Johnson FM; Ramachandra M; McAllister A
Mol Cancer Ther; 2016 Oct; 15(10):2334-2343. PubMed ID: 27439479
[TBL] [Abstract][Full Text] [Related]
10. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
[TBL] [Abstract][Full Text] [Related]
11. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
12. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
[TBL] [Abstract][Full Text] [Related]
13. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
14. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
15. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
[TBL] [Abstract][Full Text] [Related]
17. Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
Tang JC; Ren YG; Zhao J; Long F; Chen JY; Jiang Z
Life Sci; 2018 Jul; 204():71-77. PubMed ID: 29738778
[TBL] [Abstract][Full Text] [Related]
18. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
Zhou C; Qiu L; Sun Y; Healey S; Wanebo H; Kouttab N; Di W; Yan B; Wan Y
Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209
[TBL] [Abstract][Full Text] [Related]
20. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
Gritsina G; Xiao F; O'Brien SW; Gabbasov R; Maglaty MA; Xu RH; Thapa RJ; Zhou Y; Nicolas E; Litwin S; Balachandran S; Sigal LJ; Huszar D; Connolly DC
Mol Cancer Ther; 2015 Apr; 14(4):1035-47. PubMed ID: 25646015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]